First and final report of a phase II study of the poly(ADP-ribose) polymerase (PARP) inhibitor, AGO14699, in combination with temozolomide (TMZ) in patients with metastatic malignant melanoma (MM).

被引：0
|
作者：
Plummer, R.
Lorigan, P.
Evans, J.
Steven, N.
Middleton, M.
Wilson, R.
Snow, K.
Dewji, R.
Calvert, H.
机构：
[1] No Ctr Canc Treatment, Newcastle Upon Tyne, Tyne & Wear, England
[2] Chrisite Hosp, Manchester, Lancs, England
[3] Western Infirm & Associated Hosp, Beatson Oncol Ctr, Glasgow G11 6NT, Lanark, Scotland
[4] Inst Canc Studies, Birmingham, W Midlands, England
[5] Canc Res UK, Oxford, England
[6] Queens Univ Belfast, Belfast, Antrim, North Ireland
[7] Pfizer GRD, Sandwich, Kent, England
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2006年 / 24卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：456S / 456S
页数：1
相关论文
共 50 条
  • [1] Poly (ADP-ribose) polymerase-1 (PARP1) inhibitor BSI-201 in combination with temozolomide (TMZ) in malignant glioma
    Blakeley, J. O.
    Ye, X.
    Grossman, S. A.
    Mikkelsen, T.
    Rosenfeld, M. R.
    Bradley, C. R.
    Eichler, A. F.
    Nabors, L. B.
    Desideri, S.
    Supko, J. G.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [2] Final clinical, pharmacokinetic and pharmacodynamic results of the phase I study of the novel poly(ADP-ribose)polymerase (PARP) inhibitor, AG014699, in combination with temozolomide.
    Plummer, R
    Middleton, M
    Wilson, R
    Evans, J
    Jones, C
    Olson, A
    Boddy, A
    Curtin, N
    Kaufman, R
    Harris, A
    Johnston, P
    Newell, H
    Robson, L
    Dewji, R
    Calvert, H
    CLINICAL CANCER RESEARCH, 2005, 11 (24) : 9099S - 9099S
  • [3] Combination of a poly(ADP-ribose) polymerase (PARP) inhibitor and temozolomide (TMZ) suppresses growth of pediatric glioblastoma multiforme (GBM) and medulloblastoma (MB) in orthotopic mouse xenografts
    Su, Jack
    Yu, Li-Tiang
    Shu, Qin
    Adesina, Adekunle
    Pietsch, Torsten
    Bauch, Joy
    Dayton, Brian
    Giranda, Vincent
    Blaney, Susan
    Lau, Ching
    Li, Xiao-Nan
    NEURO-ONCOLOGY, 2008, 10 (03) : 375 - 375
  • [4] Phase I Study of the Poly (ADP-Ribose) Polymerase Inhibitor, AG014699, in Combination with Temozolomide in Patients with Advanced Solid Tumors
    Plummer, Ruth
    Jones, Christopher
    Middleton, Mark
    Wilson, Richard
    Evans, Jeffrey
    Olsen, Anna
    Curtin, Nicola
    Boddy, Alan
    McHugh, Peter
    Newell, David
    Harris, Adrian
    Johnson, Patrick
    Steinfeldt, Heidi
    Dewji, Raz
    Wang, Diane
    Robson, Lesley
    Calvert, Hilary
    CLINICAL CANCER RESEARCH, 2008, 14 (23) : 7917 - 7923
  • [5] Phase I/II study of the combination of decitabine (DAC) and temozolomide (TMZ) in patients (pts) with metastatic melanoma (MM)
    Tawbi, H. A.
    Beumer, J. H.
    Tarhini, A. A.
    Moschos, S. J.
    Egorin, M. J.
    Buch, S. C.
    Lin, Y.
    Kirkwood, J. M.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [6] Final results of phase I/II study of decitabine (DAC) combined with temozolomide (TMZ) in metastatic melanoma (MM).
    Beumer, J. H.
    Tawbi, H. A.
    Tarhini, A. A.
    Moschos, S. J.
    Egorin, M. J.
    Buch, S. C.
    Lin, Y.
    Kirkwood, J. M.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [7] Phase 0 pharmacodynamic, pharmacokinetic study of ABT-888, an inhibitor of poly (ADP-ribose) polymerase (PARP), in patients with advanced malignancies
    Kummar, S.
    Gutierrez, M.
    Kinders, R.
    Rubinstein, L.
    Parchment, R. E.
    Phillips, L.
    Ji, J.
    Chen, A.
    Homeffer, Y.
    Juwara, L.
    Yancey, M.
    Murgo, A. J.
    Collins, J. M.
    Tomaszewski, J. E.
    Doroshow, J. H.
    ANNALS OF ONCOLOGY, 2008, 19 : 20 - 20
  • [8] Preliminary results of a phase I trial of ABT-888, a poly(ADP-ribose) polymerase (PARP) inhibitor, in combination with cyclophosphamide.
    Tan, A. R.
    Gibbon, D.
    Stein, M. N.
    Moss, R. A.
    Karantza, V.
    Lin, H.
    Gounder, M.
    Chen, A. P.
    Egorin, M. J.
    DiPaola, R. S.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [9] A phase I trial of veliparib, an inhibitor of poly(ADP-ribose) polymerase (PARP), and topotecan (TPT) in patients with solid tumors.
    Hendrickson, Andrea Elisabeth Wahner
    Menefee, Michael E.
    Hartmann, Lynn C.
    Long, Harry J.
    Northfelt, Donald W.
    Reid, Joel M.
    Boakye-Agyeman, Fleix
    Flatten, Karen S.
    Poirier, Guy G.
    Lensing, Janet
    Erlichman, Charles
    Kaufmann, Scott H.
    Haluska, Paul
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [10] Final Results of a Randomized Phase II Study Demonstrating Efficacy and Safety of BSI-201, a Poly (ADP-Ribose) Polymerase (PARP) Inhibitor, in Combination with Gemcitabine/Carboplatin (G/C) in Metastatic Triple Negative Breast Cancer (TNBC)
    O'Shaughnessy, J.
    Osborne, C.
    Pippen, J.
    Patt, D.
    Rocha, C.
    Ossovskaya, V
    Sherman, B.
    Bradley, C.
    CANCER RESEARCH, 2009, 69 (24) : 686S - 687S
12345